title: Mediator release from human lung under conditions of reduced oxygen tension.
abstract: Although the mechanism underlying hypoxic pulmonary vasoconstriction remains undefined, various reports have suggested that mast cells and cell-derived mediators may be important in the production of this phenomenon. We investigated the effect of reducing oxygen tension on the release from human lung fragments of the mast cell-derived mediators histamine, prostaglandin (PG) D2 and peptide leukotrienes, as well as the release of the largely non-mast cell-derived mediators PGE2, PGF2 alpha, prostacyclin metabolite (6-keto-PGF1 alpha) and the thromboxane A2 metabolite (thromboxane B2). The effect of reducing oxygen tension on both basal mediator release and release triggered by goat antihuman immunoglobulin E was studied. Reducing pO2 of buffer in which lung fragments were placed from 161 to 54 mm Hg resulted in no spontaneous release of histamine, PGD2 or peptide leukotrienes. However, hypoxia had a marked effect on mediator release triggered by goat antihuman immunoglobulin E. Although net histamine release was relatively unaffected (control 13.9 +/- 2.7%, hypoxic 12.7 +/- 2.1%), hypoxic treatment resulted in an 89% inhibition of PGD2 release (control 47.7 +/- 17.4 ng/g of lung, hypoxic 5.26 +/- 1.91 ng/g of lung) and an 81% inhibition of peptide leukotriene release (control 22.5 +/- 7.6 ng/g of lung, hypoxic 4.37 +/- 2.4 ng/g of lung). Similar inhibition was seen for non-mast cell-derived mediators, including PGF2 alpha, prostacyclin metabolite and thromboxane B2, and probably for PGE2. We conclude that hypoxic treatment of human lung fragments in vitro results in no spontaneous release of preformed or newly formed mediators but that it markedly alters mediator release after goat antihuman immunoglobulin E triggering.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D006636:Histamine Release; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D007073:Immunoglobulin E; D017999:Leukotriene E4; D008168:Lung / Q000378:metabolism*; D008407:Mast Cells / Q000378:metabolism; D010100:Oxygen; D015230:Prostaglandin D2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011457:Prostaglandins D / Q000378:metabolism*; D013189:SRS-A / Q000031:analogs & derivatives / Q000378:metabolism*; D013928:Thromboxane A2 / Q000378:metabolism; D013929:Thromboxane B2 / Q000378:metabolism
chemical_list: D011457:Prostaglandins D; D013189:SRS-A; D007073:Immunoglobulin E; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D017999:Leukotriene E4; D011451:Prostaglandin-Endoperoxide Synthases; D015230:Prostaglandin D2; D010100:Oxygen